ChemicalBook--->CAS DataBase List--->2135341-09-0

2135341-09-0

2135341-09-0 Structure

2135341-09-0 Structure
IdentificationBack Directory
[Name]

(E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid
[CAS]

2135341-09-0
[Synonyms]

LX-039
2-Propenoic acid, 3-[4-[2-(2-chloro-4-fluorophenyl)-1-(3-chloro-1H-indol-2-yl)-1-buten-1-yl]phenyl]-
(E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid
2-hydroxy-N,N,N-trimethylethan-1-aminium (E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylate
[Molecular Formula]

C27H20Cl2FNO2
[MOL File]

2135341-09-0.mol
[Molecular Weight]

480.36
Chemical PropertiesBack Directory
[Boiling point ]

638.7±55.0 °C(Predicted)
[density ]

1.366±0.06 g/cm3(Predicted)
[pka]

4.40±0.10(Predicted)
Hazard InformationBack Directory
[Uses]

LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity[1].
[in vivo]

LX-039 (2.5 mg/kg; PO and IV; single) exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure[1].
LX-039 (6.5 mg/kg, 20 mg/kg and 60 mg/kg; PO; daily for 21 days) inhibits tumor growth in a dose-dependent manner[1].
LX-039 (1 mg/kg; PO and IV; single) displays a moderate to low clearance (Cl) plus good oral bioavailability (F%) in both rat and dog[1].
Pharmacokinetic Parameters of LX-039 in CD-1 mouse[1].

IVPO (2.5 mg/kg)
Vd (L/kg)0.5
CL (mL/min/kg)1.4
Cmax (nM)1873
AUC0-24 (nM·h)15329
F (%)60.1

Pharmacokinetic Parameters of LX-039 in SD rat and Beagle dog[1].
SD RatBeagle Dog
Vd (L/kg, iv)20.42
CL (mL/min/kg, iv)7.70.84
C0, iv (nM), 1 mg/kg261012800
AUC0-24, iv (nM·h), 1 mg/kg482043800
Cmax, po (nM), 1 mg/kg3812550
AUC0-24, po (nM·h), 1 mg/kg270024200
F (%)5655
[IC 50]

Estrogen receptor: 2.29 nM (EC50)
[References]

[1] Lu J, Chan CC, Sun D, et al. Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD). Bioorg Med Chem Lett. 2022;66:128734. DOI:10.1016/j.bmcl.2022.128734
2135341-09-0 suppliers list
Company Name: Nantong Hi-Future Biotechnology Co., Ltd  
Telephone: +86-0513; 18051384581
Website: https://www.chemhifuture.com/
Company Name: TargetMol Chemicals Inc.  
Telephone: 15002134094
Website: https://www.targetmol.cn/
Tags:2135341-09-0 Related Product Information
129453-61-8 438-67-5 57-63-6 50-28-2 1428-67-7 1161002-05-6